Pharmaceutical Medicine

, Volume 32, Issue 2, pp 143–148 | Cite as

Unregistered Medical Products Detected by Malaysia’s Pharmacy Enforcement Division During Routine Inspection: A Cross-Sectional Study among Selected Mainstream Medicines’ Retailers in the State of Sarawak

  • Chuo Yew Ting
  • Shing Chyi Loo
  • Sui Theng Sim
  • Eng Chun Tee
  • Mohamed Azmi Hassali
  • Abu Hassan Alshaari Abd Jabar
  • Shahren Ahmad Zaidi Adruce
  • Benodict Apok Talin
Original Research Article
  • 21 Downloads

Abstract

Background

Globally, substandard and falsified medical products (SFMPs) have been a major public health concern, and can be devastating to patients’ safety. In Malaysia, the detection of unregistered medical products (UMPs) by the Pharmacy Enforcement Division (PED) officers among mainstream medicines’ retailers (MMR), aims to curb the distribution of SFMP to the public.

Objective

This study explored the UMP detected by PED officers during routine inspections among the MMR that were sampled for the screening of UMP. The MMR include private medical clinics (PMCs), retail pharmacies (RPs) and non-pharmacy drug stores (NPDS).

Methods

This was a retrospective cross-sectional study that gathered the relevant information using a data collection form, from the routine inspection reports (RIRs) of the MMR in Sarawak throughout the year 2016. Of the 361 PMCs, 242 RPs and 894 NPDS that underwent routine inspection during the study period, a total of 20 PMC, 23 RP and 43 NPDS were selected by the senior PED officer in charge of the inspection unit to undergo screening of UMPs and were included for the purpose of this study. The top 10–12 MP, which were commonly used and had high turnover, based on the sales record of every premises, were sampled. The methods used to detect UMP were through the searching of online product registration database “QUEST 3”, the vetting of the Meditag™ Hologram (MH) using its decoder and the vetting of the MH serial numbers through Meditag Online Ordering System. Data analyses were conducted with SPSS V20.0.

Results

From the 86 premises selected for screening of UMPs, a total of 888 MPs were sampled and recorded into RIR. It was found that 4 out of 888 (0.45%) samples were UMP. Each the UMPs were found in NPDS. In term of types of the UMP found, two were traditional medicines, one was a controlled medicine and one was an over-the-counter medicine.

Conclusion

The findings of this study provide preliminary information to relevant authorities on the UMPs detected by PED officers during routine inspections among selected MMRs.

Notes

Acknowledgements

The authors would like to express their gratitude to Director General of Health Malaysia YBhg. Datuk Dr Noor Hisham Bin Abdullah for his approval to publish this manuscript. The authors are obliged to thank the Director of Sarawak State Health Department Dr. Jamilah Hashim for her approval on the data collection of this study and unconditional support in this study. Last but not least, credits to all enumerators from Sarawak Pharmacy Enforcement Branch who devoted their efforts unreservedly in the data collection process to make this study possible.

Author contributions

All authors read and approved the final manuscript.

Compliance with Ethical Standards

Ethical approval

The study was reviewed and approved by the Ministry of Health Malaysia Research Ethics Committee (MREC) on December 23, 2016 with registration number NMRR-16-2147-33176. All the data are restricted to the principal investigators and solely used for research purposes. The study was conducted in compliance with ethical principles outlined in the Declaration of Helsinki and Malaysian Good Clinical Practice Guideline.

Consent for publication

No personal information will be disclosed, and subjects will not be identified when the findings of the survey are published. This study had obtained approval from Director General of Health Malaysia for publication’s approval.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of interests

Chuo Yew Ting, Shing Chyi Loo, Sui Theng Sim, Eng Chun Tee, Mohamed Azmi Hassali, Abu Hassan Alshaari Abd Jabar, Shahren Ahmad Zaidi Adruce, Benodict Apok Talin declare that they have no conflict of interest.

Funding

All the overhead expenses were covered by the operating fund of Pharmaceutical Services Division, Sarawak State Health Department. There are no other funding sources.

Supplementary material

40290_2018_229_MOESM1_ESM.pdf (261 kb)
Supplementary material 1 (PDF 261 kb)

References

  1. 1.
    Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open. 2013;3(8):e002923.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    WHO member state mechanism on substandard/spurious/falselylabelled/falsified/counterfeit (SSFFC) medical products working definitions. In: Official Portal of World Health Organization. http://www.who.int/medicines/regulation/ssffc/A70_23-en1.pdf?ua=1. Accessed 13 Dec 2017.
  3. 3.
    Buowari OV. Fake and counterfeit drug: a review. Afrimedic J. 2013;3(2):1–4.Google Scholar
  4. 4.
    Lancet. Fighting fake drugs: the role of WHO and pharma. Lancet. 2011;377(9778):1626.Google Scholar
  5. 5.
    El-Jardali F, Akl E, Fadlallah R, Oliver S, Saleh N, El-Bawab L, et al. Interventions to combat or prevent drug counterfeiting: a systematic review. BMJ Open. 2015;5(3):e006290.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fadlallah R, El-Jardali F, Annan F, Azzam H, Akl E. Strategies and systems-level interventions to combat or prevent drug counterfeiting: a systematic review of evidence beyond effectiveness. Pharm Med. 2016;30(5):263–76.CrossRefGoogle Scholar
  7. 7.
    Amin AA, Kokwaro GO. Antimalarial drug quality in Africa. J Clin Pharm Ther. 2007;32(5):1–15.CrossRefGoogle Scholar
  8. 8.
    Ting CY, Lee KS, Tan RT, Ang WC, Ming LC. An exploratory study on the consumers use of medicine in the state of Sarawak, Malaysia. J Young Pharm. 2016;8(4):477–82.CrossRefGoogle Scholar
  9. 9.
    Malaysian Laws on Poisons and Sale of Drugs. Petaling Jaya: International Law Book Services; 2010.Google Scholar
  10. 10.
    National Pharmaceutical Regulatory Division. Drug Registration Guidance Document Second Edition September 2016. In: Official Portal National Pharmaceutical Regulatory Agency. 2017. http://npra.moh.gov.my/images/Guidelines_Central/guideline-DRGD/Complete_DRGD_with_appendices_MARCH_2017.pdf. Accessed 23 June 2017.
  11. 11.
    Ministry of Health Malaysia. Malaysian National Medicines Policy 2nd Edition. In: Essential Medicines and Health Products Information Portal. A World Health Organization resource. 2013. http://apps.who.int/medicinedocs/en/m/abstract/Js22203en/. Accessed 23 Mar 2017.
  12. 12.
    Mydin H, Stevens P. Fake medicines in Asia. In:https://www.researchgatenet. 2013. https://www.researchgate.net/publication/235912758_Fake_medicines_in_Asia. Accessed 5 Feb 2017.
  13. 13.
    Sistem My.Pharma-C. In: Mypharma-c.pharmacy.gov.my. 2016. https://www.mypharma-c.pharmacy.gov.my. Accessed 13 Dec 2017.
  14. 14.
    Garis Panduan Serbuan. Petaling Jaya: Bahagian Perkhimatan Farmasi; 2017.Google Scholar
  15. 15.
    About Meditag™. In: Mediharta.com.my. 2004. http://www.mediharta.com.my/benefits.shtml. Accessed 13 Dec 2017.
  16. 16.
    Using MTOS?. In: Mediharta.com.my. 2004. http://www.mediharta.com.my/mtos.shtml. Accessed 13 Dec 2017.
  17. 17.
    NPRA - QUEST3 + Products Search. In: Official Portal National Pharmaceutical Regulatory Agency. http://npra.moh.gov.my/index.php/2016-08-02-06-37-27/products-search/notification-search-2. Accessed 13 Dec 2017.
  18. 18.
    Spss I. IBM SPSS statistics base 20. Chicago: SPSS Inc.; 2011.Google Scholar
  19. 19.
    Zulkifli NW, Aziz NA, Hassan Y, Hassali MA, Bahrin NL, Ahmad A. Are we on the right track?: overview of unregistered drugs in Malaysia. J Pharm Pract Community Med. 2016;2(4):107–15.Google Scholar
  20. 20.
    Lum M. The counterfeit menace. In: The Star Online. 4 Jan 2015. https://www.thestar.com.my/lifestyle/health/2015/01/04/the-counterfeit-menace/. Accessed 17 Jan 2018.
  21. 21.
    Noor Hisham Abdullah. In: Facebook. https://www.facebook.com/DGHisham/posts/920448017979087. Accessed 17 Jan 2018.
  22. 22.
    Ministry of Health Malaysia. Pharmacy Program Annual report 2014. In: Official Portal of Pharmaceutical Services Division. Ministry of Health. 2015. http://www.pharmacy.gov.my/v2/sites/default/files/document-upload/ar-pharmacy-2014-final_0.pdf. Accessed 23 Mar 2017.
  23. 23.
    Lon CT, Tsuyuoka R, Phanouvong S, et al. Counterfeit and substandard antimalarial drugs in Cambodia. Trans R Soc Trop Med Hyg. 2006;100(11):1019–24.CrossRefPubMedGoogle Scholar
  24. 24.
    Prazuck T, Falconi I, Morineau G, et al. Quality control of antibiotics before the implementation of an STD program in Northern Myanmar. Sex Transm Dis. 2002;29:624–7.CrossRefPubMedGoogle Scholar
  25. 25.
    The World Bank in Malaysia. In: Worldbank.org. 2017. http://www.worldbank.org/en/country/malaysia/overview. Accessed 13 Dec 2017.
  26. 26.
    Muthukumar R, Rentap L. Sarawakians the poorest in Malaysia. In: Free Malaysia Today. 2014. http://www.freemalaysiatoday.com/category/nation/2014/09/23/sarawakians-the-poorest-in-malaysia/. Accessed 13 Dec 2017.
  27. 27.
    New Hologram Meditag. In: Official portal of Pharmaceutical Services Programme Ministry of Health Malaysia. 2015. https://www.pharmacy.gov.my/v2/en/content/new-hologram-meditag.html. Accessed 13 Dec 2017.
  28. 28.
    Ting CY, Abd Wahab MS, Lee KS, Tan RT, Ming LC. A cross-sectional study on the use of, preference for, and perceived reliability of mass media for drug-related information among the general public in Sarawak. Ther Innov Regul Sci. 2017;51(2):212–20.CrossRefGoogle Scholar
  29. 29.
    Newton PN, Lee SJ, Goodman C, Fernández FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJ, Kokwaro GO, Lindegårdh N. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med. 2009;6(3):e1000052.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Maize H, Mavity M, McCord J, Schramm S, Stepanovic M, Wintczak D. Method to improve drug safety in Africa: a pharmaceutical learning module. J Purdue Undergrad Res. 2017;7(1):3.Google Scholar
  31. 31.
    Petersen A, Held N, Heide L. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab. PLoS One. 2017;12(9):e0184165.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Chuo Yew Ting
    • 1
    • 2
  • Shing Chyi Loo
    • 1
  • Sui Theng Sim
    • 1
  • Eng Chun Tee
    • 1
  • Mohamed Azmi Hassali
    • 3
  • Abu Hassan Alshaari Abd Jabar
    • 4
  • Shahren Ahmad Zaidi Adruce
    • 2
  • Benodict Apok Talin
    • 1
  1. 1.Pharmacy Enforcement BranchState Health DepartmentKuchingMalaysia
  2. 2.Institute of Borneo StudiesUniversity Malaysia SarawakSamarahanMalaysia
  3. 3.Discipline of Social and Administrative Pharmacy, School of Pharmaceutical SciencesUniversiti Sains MalaysiaPenangMalaysia
  4. 4.Pharmaceutical Services DivisionState Health DepartmentKuchingMalaysia

Personalised recommendations